Business Wire

Anji Pharmaceuticals Acquires Late-Stage Clinical Asset and Readies for Ph3 Trials in Type 2 Diabetes with Chronic Kidney Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anji Pharmaceuticals, Inc. (“Anji” or “the Company”) today announced the acquisition of global development rights for a novel delayed-release formulation of ...
FierceBiotech

Anji Pharma nabs $70M for late-stage diabetes treatment, ex-Novartis asset

Anji Pharma wants to bring a Type 2 diabetes and chronic kidney disease treatment along with a constipation drug to market, and now the biotech has $70 million to bankroll clinical trials. The ...
Business Wire

Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease

BOSTON & NEW YORK--(BUSINESS WIRE)--Anji Pharmaceuticals and Population Health Partners today announced that they have entered into a strategic collaboration, bringing together two complementary teams ...
MedCity News

Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz model

Anji Pharma, a biotech with outposts in China and the U.S., has raised $70 million to continue clinical development of two metabolic disorder drugs and begin work on an oncology pipeline. The cash ...